SUNNYVALE, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq:SILK) (“Silk Road Medical”) today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $20.00 per share. All of the shares of common stock are being offered by Silk Road Medical. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Silk Road Medical’s common stock is expected to begin trading on The Nasdaq Global Market on April 4, 2019, under the ticker symbol “SILK”. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Silk Road Medical, are expected to be approximately $120 million. Silk Road Medical will not receive any proceeds from the sale of shares of common stock by the selling stockholders if the underwriters exercise their option to purchase additional shares. The offering is expected to close on April 8, 2019, subject to the satisfaction of customary closing conditions.
Read More: https://www.globenewswire.com/news-release/2019/04/03/1796738/0/en/Silk-Road-Medical-Announces-Pricing-of-Initial-Public-Offering.html
Via: GlobeNewsWire Medical device company Silk Road Medical (SILK) priced its initial public offering at 20 a share, at the high end of its recently raised expected range. The Silk Road IPO garnered lots of attention from investors, with one IPO research firm giving the company its highest rating. Silk Road stock will start trading Thursday. Via: NASDAQ Silk Road Medical, which sells medical devices to treat carotid artery disease, announced terms for its IPO on Monday. Via: MedTech Dive Dive Brief: Via: NASDAQ Silk Road Medical, which sells medical devices used in TCAR for the treatment of carotid artery disease, filed on Monday with the SEC to raise up to $86 million in an initial public offering. Via: PR Newswire LEXINGTON, Mass., Feb. 27, 2019 /PRNewswire/ -- Tepha Inc. announced today the initiation of a pilot clinical evaluation of the Company's P4HB regenerative polymer scaffold for the surgical treatment of stress urinary incontinence (SUI). The study was initiated in Cape Town, South Africa in partnership with the Pelvic Floor Foundation of South Africa ("PFFSA") and the University of Cape Town. The first procedures were performed by co-principal investigators, Dr. Stephen Jefferyof the University of Cape Town and Professor Jan-Paul Roovers of the Academic Medical Center, Amsterdam, The Netherlands. The Cape Town SUI study represents the first clinical application of Tepha's P4HB polymer technology in the field of urogynecology. Based in Lexington, MA, Tepha is the pioneer developer and exclusive supplier of the P4HB polymer for medical applications that include hernia repair, plastic surgery, tendon & ligament repair, and wound closure. Via: TechCrunch After winding down its consumer-oriented operations last July, mental health startup Lantern has partnered with larger mental health providers to license its IP. In addition to licensing its IP to Omada Health, Lantern has licensed its tech to Spring Health, Ginger and two others. 1NEWSISET 2019Surmounting Minor Stroke: New Devices, TCAR Aim to Cut Risk of Carotid Artery Stenting1/31/2019
Embolic protection, new stents, and TCAR are narrowing the gap between CAS and CEA, but medical therapy could still hold its own in CREST-2. Via: BusinessWire Dr. Michael Aragon and Stacey Porter Bring Wealth of Clinical and Organizational Expertise During Time of Company Grow Via: Business Insider When Sean Duffy, the cofounder and CEO of a digital-health startup called Omada Health, took his first look at the results of his new diabetes-treatment program, he noticed a disturbing trend. |
Archives
October 2023
|